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Abstract: Based on the biological properties of epoxyquinols from natural sources, the title
compound was synthesised as a potential antitumor agent. Its molecular structure was par-
tially confirmed by NMR studies. The detailed structure was established by X-ray analysis
revealing two symmetry independent molecules in the asymmetric unit each consisting of
four fused rings with the C(10) β-oriented hydroxy group and β-oriented O atom bridging
C(4) and C(5). The conformation of A ring in both conformers A and B is boat (B3,6), while
rings B and C are chairs (1C4) and the five-membered D ring is in an envelope (E2) confor-
mation. The in vitro antitumor activity of title compound and its 17β-acetoxy analogue
against HeLa and Fem-x cells revealed IC50 values of 5.7 and 7.1 µM, and 2.25 and 1.58
µM, respectively. Corresponding quinols were tested on 47 cell lines with 10β-hydroxy-
17β-acetoxyestra-1,4-dien-3-one being most active against leukemia SR cells (GI50 = 0.17
µM).
Keywords: Steroids, epoxyquinol, quinol, X-ray crystallography, antitumor activity.
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Introduction
A large number of natural as well as synthetic compounds with an epoxyquinol moiety show vari-
ous biological activities (Figure 1) [1], being at the same time useful intermediates in the synthesis of
cyclitols (conduritols, inositols) [2], which are also of biological importance [3].
O
N
H
OH
O
OO
O
N
H
OH
O
OH
NH
O
O
OH
O
O
OAc
O
O
OH
Br
Manumycin A
(antibiotic activity)
LL-C 10037α
(antitumor activity)
Tricholomenyn A
(antibiotic activity)
Bromoxone
(antitumor activity)
Figure 1.
The incorporation of such substructures into the steroidal framework could lead to synthetically and
biologically important compounds [4]. Synthesis of the steroidal epoxyquinol 3 (along with quinol 2)
was achieved in good yield [5], but no direct determination of configuration of the epoxide ring in 3
has been made [6].
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The determination of the configuration of 3 was undertaken as a part of our program aimed at fully
characterising these and related compounds in an attempt to synthetically expand the structural frame-
works of natural compounds in an analogous way for further structure-activity studies.
Here we present the structure determination of epoxyquinol 3 and in vitro antitumor activity of 3
and of 17β-acetoxy analogue 5 (Figure 5) against HeLa and Fem-x cell lines. The antitumor activity of
corresponding quinols 2 and 4 will also be presented.
Results and discussion
Synthesis
The epoxyquinol 3 (Scheme 1) was synthesised either from estrone 1 (two step one-pot reaction) or
from quinol 2, using the oxidation system consisting of m-CPBA / (BzO)2 / hν  as described in [4], [5],
[9].
Structure Elucidation
The constitution of the epoxyquinol 3 (mp = 201-203oC (colourless needles, benzene)) was derived
from the following data: [α]D24 = +294 (c = 1.0, chl.). IR (KBr) cm-1: 3359(s), 2955(w), 1725(s),
1686(s), 1152(w). MS (CI, isobutane, m/e): 303 (MH+). λmaxMeOH=234 nm(8200). Anal. calc. for
C18H22O4 × 2/3 C6H6 (354.45): C 74.55, H 7.39, found: C 74.61, H 7.12.
Molecular modelling indicated that the configuration of oxirane ring cannot be determined using
NOE difference spectroscopy: in both α and β configuration of the epoxide, the distance between H-
C(4) and all other NOE-related protons (OH, Hα-C(6) and Hβ-C(6) is less than 2.7 Å). Therefore we
determined the structure of 3 by X-ray analysis.
X-ray crystallography
Crystals obtained by slow evaporation of a benzene solution at room temperature were studied by
X-ray diffraction procedures. Selected geometrical parameters, bond distances, bond angles and tor-
sion angles are listed in Table 6 according to the numbering scheme displayed in Figure 2.
Perspective view of the crystal unit of 3 is depicted in Figure 2 [15]. The structure consists of two
V\PPHWU\ LQGHSHQGHQWPROHFXOHV LQ WKHDV\PPHWULFXQLW HDFKZLWK IRXU IXVHG ULQJVZLWK RULHQWHG
K\GUR[\JURXSDQGRULHQWHG2DWRPEULGJLQJ&DQG&DWRPV
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Figure 2. ORTEP [15] drawing of the molecules A (blue) and B (red) with the non-H atom labeling
scheme. The displacement ellipsoids are drawn at 25% probability.
Geometrical analysis confirmed the existence of two C-O double bonds, with distances C(3)-O(3) =
1.217(4)Å (A), 1.217(4)Å (B) and C(17)-O(17) = 1.212(3) Å (A), 1.212(4) Å (B)  for molecules A and
B, respectively. The analysis of the steroid rings by calculating puckering parameters [7] and asym-
metric factors [8] (Table 1) has shown that the symmetry independent molecules A and B are of very
similar conformations. This was also confirmed by fitting the molecules into each other.
The A ring in both molecules is in boat B3,6 conformation, B and C steroid rings are chairs with 1C4
conformations, while the five membered D ring is in envelope E2 conformation. The energetically
more stable conformation of steroid rings in the molecule under study, compared to the methoxy-
quinone derivative [9], indicate a less strained and hence lower energy conformation for this com-
SRXQGLKHYDOXHVRI UHOHYDQW WRUVLRQ DQJOHV >2$%&$%&$%2$%  
(A), 74.4(3)° (B)] reveal the cis junction between A/B rings, trans junction [H(9)A(B)-C(9)A(B)-
C(8)A(B)-H(8)A(B) = -177.7(2)° (A), 177.9(2)° (B)] between B/C rings and [C(18)A(B)-C(13)A(B)-
C(14)A(B)-H(14)A(B) = -179.5(2)° (A), 180.0(2)° (B)] between C/D steroid rings. The best plane
through the rings B and C in the molecule A form an angle of 71.35° with the corresponding plane of
the molecule B (Figure 2).
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Table 1. Puckering parameters and asymmetry factors.
ring mole-
cule
Q(Å) ϕ(°) θ(°) fCs(Å) fC2(Å) cNd
A A 0.267(3) 117.6(6) 96.3(6) 0.011(1)[C3A]
0.026(1)[C1A-C2A]
0.061(2)[C1A]
0.079(3)[C2A]
B3,6
B 0.215(3) 121.4(8) 102.6(8) 0.0050(1)[C3B]
0.038(2)[C1B-C2B]
0.060(3)[C1B]
0.057(3)[C2B]
B3,6
B A 0.566(3) 203(5) 3.6(3) 0.011(1)[C5A]
0.017(1)[C6A]
0.035(1)[C7A]
0.0030(1)[C5A-C6A]
0.027(1)[C6A-C7A]
0.023(1)[C7A-C8A]
1C4
B 0.553(3) 151(6) 2.9(3) 0.011(1)[C5B]
0.023(1)[C6B]
0.015(1)[C7B]
0.020(1)[C5B-C6B]
0.020(1)[C6B-C7B]
0.0010(1)[C7B-C8B]
1C4
C A 0.571(3) 270(3) 5.0(3) 0.041(1)[C8A]
0.021(1)[C9A]
0.032(1)[C11A]
0.035(1)[C8A-C9A]
0.000(1)[C9A-C11A]
0.035(1)[C11A-C12A]
1C4
B 0.586(3) 316(4) 3.8(3) 0.022(1)[C8B]
0.031(1)[C9B]
0.011(1)[C11B]
0.031(1)[C8B-C9B]
0.023(1)[C9B-C11B]
0.008(1)[C11B-C12B]
1C4
D A 0.428(4) 29.4(5) 0.050(1)[C14A] 0.065(1)[C16A] E2
B 0.422(4) 32.2(6) 0.028(1)[C14B] 0.080(2)[C16B] E2
Table 2. Geometry (Å,º ) of hydrogen-bond nets and short contact bridged by an hydrogen atom.
X – H…Y X– H  [Å] H…Y [Å] X…Y [Å] X – H…Y [°]
O(10) – H(10)…O(17)i   A
                                         B
0.818(2)
0.821(2)
2.100(2)
1.963(2)
2.873(3)
2.779(3)
157.5(1)
172.2(2)
C(16) – H(162)…O(4)ii   A
                                         B
0.965(3)
0.972(4)
2.521(2)
2.356(3)
3.411(4)
3.201(5)
153.3(2)
145.0(2)
C(9A) – H(9A)…..O(3B)iii 0.981(2) 2.373(3) 3.342(4) 169.4(1)
C(2A) – H(2A)…..O(17B)i 0.934(3) 2.691(3) 3.406(4) 133.9(2)
C(2B) – H(2B)…..O(10B)v 0.933(4) 2.663(2) 3.447(4) 142.0(2)
C(4) – H(4)……..O(10)iv  A 0.980(3) 2.664(2) 3.637(3) 172.0(2)
Symmetry code: (i) x–1, y, z   (ii) x+1,y,z (iii) –x,y-1/2,-z  (iv) -x,y-1/2,-z+1 (v) -x,y+1/2,-z.
Analysis of the molecular packing in the unit cell revealed a weak C-H…O intermolecular hydro-
gen contacts (Table 2) and a very strong intermolecular hydrogen bond [O(10) - H(10)…O(17) i =
2.873(3)Å in molecule A and 2.779(3) Å in molecule B]. The above mentioned strong hydrogen bonds
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lead to the creation of the chains consisting of only one type of molecules, A or B. These chains are
stacked alternatively along a-axis and bonded by weaker C-H….O type bonds, which results in a lay-
ered packing of the molecules parallel to the ab plane (Figure 3).
Figure 3. The crystal packing for the unit cell projected along the b-axis. The arrows denote hydrogen
bonds (two strongest ones).
NMR analysis
Appearance of the signal at 3.33 ppm (d, J = 2.2 Hz) in 1H NMR spectrum indicates the existence of
oxirane moiety in compound 3 (H-C(4)). Doublet at 6.68 ppm (J = 10.6 Hz) belongs to H-C(1), which
is coupled to H-C(2); consequently, doublet of doublets at 5.77 ppm (J = 10.6, 2.2 Hz) is assigned to
H-C(2), and its J-values are a measure of coupling to H-C(1) ("ortho"-H) and H-C(4) (long-range W
scalar coupling through 4 σ-bonds including the carbonyl function). In addition, connection of signals at
6.68, 5.77 and 3.33 ppm was confirmed by HOMO decoupling experiments: irr. at 6.68 ppm → 5.77
ppm, d, J = 2.2 Hz; irr. at 5.77 ppm → 6.68 and 3.33 ppm, both s; irr. at 3.33 ppm → 6.68 and 5.77
ppm, both d, J = 10.6 Hz. Singlet at 5.79 ppm, exchangeable with D2O, belongs to OH, and the one at
0.81 ppm to the angular methyl group hydrogens.
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a) b)
Figure 4. a) 1H NMR spectrum of compound 3; b) HD 1H NMR spectrum (irradiated signal at 5.77
ppm) of compound 3.
a) b) c)
Figure 5. Selected spectra of epoxyquinol 3.
a) C,H-COSY; b) H,H-COSY; c)13C NMR-DEPT.
Assignation of selected spin-active nuclei is obtained by using comparative analysis of DEPT 13C
and 2D correlated NMR spectra (H,H and C,H COSY) (Table 3).
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Table 3. C- and H-chemical shifts of 10β-hydroxy-4β,5β-epoxyestr-1-en-3,17-dione (3; DMSO-d6).
Position δC (ppm) δH (ppm)
1 153.06 6.68 (d, J = 10.6)
2 122.33 5.77 (dd, J = 10.6, 2.2)
3 195.14 -
4 59.56 3.33 (d, J = 2.2)
5 64.59 -
6 28.15 2.32a (m, Hβ),  1.24 (m, Hα)
8 33.62 1.87 (m, Hβ)
9 54.19 1.03 (m)
10 71.74 -
13 46.93 -
17 219.54 -
18 13.30 0.81 (s)
OH - 5,79 (s)
a Values for presented multiplets are mean of signal in C,H COSY spectrum.
Biochemistry
In this work, the antiproliferative action of synthetic compounds 3 and 5 derived from estrone on
two human neoplastic cell lines, HeLa and Fem-x, in vitro, was determined. Presented are also the ac-
tivities [10] of corresponding quinols 2 and 4 (Figure 6).
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Figure 5.
The epoxyquinols 3 and 5 expressed the dose-dependent antiproliferative action toward investigated
cell lines. In order to compare the extent of the antiproliferative action between neoplastic cell lines of
different origin, IC50 were determined under the same conditions by MTT test. They were very similar
for HeLa and Fem-X cells and mean values from three independently performed experiments for 48 h
of continuous agent’s action (epoxyquinols 3 and 5, respectively) were 5.7±1.3 and 2.25±0.35 µM for
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HeLa, and 7.1 ± 2.25 and 1.58 ± 0.04 µM for Fem-x cells (Table 4). Morphological examination of
target cells by inverted microscope showed that the cytotoxic action resulted in cells rounding in the
presence of agent in concentration higher than 6 µM and / or cell ballooning in the concentration
higher than 12 µM.
Table 4a. In vitro antitumor activity of epoxyquinols 3 and 5, and quinols 2 and 4.
Compound IC50 (µM) b GI50 (µM) c
HeLa Fem-x Leukemia
SR
Leukemia
CCRF-CEM
3 5.73 7.10
5 2.25 1.58
2 74.30 26.40
4 0.17 d 11.90
a
 48 h of continuous agent’s action; b IC = Inhibition concentration; c GI = Growth inhibition. Out of
47 cell lines tested, presented are only the ones where highest activity of 2 and 4 was established; d TGI
(Total GI) = 1.63 µM, LC50 > 100 µM.
The title compounds 2 and 4 were in vitro tested by NCI at a minimum of five concentrations at 10-
fold dilutions. A 48 hours continuous drug exposure protocol is used, and a SRB (sulforhodamine B)
protein assay is used to estimate cell survival or growth. The GI50 is interpolated value representing
concentration at which the percentage growth is +50. Presented results indicate that quinol 2 is moder-
ately active against both leukemia cell lines, while analogue compound 4 is much more selective.
Both compounds, 2 and 4, were also tested for their antiviral activity. The procedure used in the
NCI's test for agents active against HIV virus is designed to detect agents acting at any stage of the vi-
rus reproductive cycle. The assay involves the killing of T4 lymphocytes by HIV. Small amounts of
HIV are added to cells, and two cycles of virus reproduction are necessary to obtain the required kill-
ing. Agents that interact with virions, cells or virus gene-products to interfere with viral activities, will
protect cells from cytolysis. All tests are compared with at least one positive (AZT-treated) control
performed at the same time under identical conditions. Both quinols are confirmed inactive, having
IC50 > 2×10-4 M against CEM-SS cell line.
Although the two pairs of compounds, epoxyquinols 3 and 5 and quinols 2 and 4, were tested on
different cell lines, one observation merits comment: In both cases estradiol derived compounds 4 and
5 (possessing 17β-acetoxy group instead of 17-oxo functionality as in 2 and 3) exhibited stronger ac-
tivity towards target cell lines. Compound 4 is also highly active against melanoma SK-MEL-5 cell
lines with GI50 = 3.14 µM (quinol 2, GI50 = 82.0 µM).
Our further investigation in this area will be focused to the synthesis and antitumor activity evalua-
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tion of the influence of the oxirane ring position and its stereochemistry, as well as on the influence of
C(17) substituent in estrane derived quinols.
Experimental
General
Melting points were determined on a Mikro-Heiztisch Boetius PHMK apparatus and were not cor-
rected. IR and UV spectra were recorded on Perkin-Elmer FT-IR 1725X and Beckman DU-50 spectro-
photometers, respectively. 1H and 13C NMR spectra were recorded on Bruker AM-250 spectrometer.
Chemical shifts were expressed as ppm (δ) values and coupling constant (J) in Hz. Mass spectra were
taken on a Finnigan-MAT 8230 spectrometer.
All compounds were synthesised and the relevant data are presented in refs. [4], [5] and [9].
X-ray crystallography
A colourless plate-like crystal of dimensions 0.5×0.3×0.2 mm was mounted on an STOE four circle
GLIIUDFWRPHWHUHTXLSSHGZLWK&X..UDGLDWLRQDQG1LILOWHU&HOOSDUDPHWHUV7DEOHZHUHGHWHUPLQHG
by least-squares refinement of diffractometer angles for 59 reflections collected in the range 15.0 ≤≤
31.0º. Three standard reflections were monitored every 90 min but no considerable intensity variations
ZHUH UHFRUGHG 5HIOHFWLRQVZHUH UHFRUGHGZLWK & VFDQ LQ WKH UDQJH  ≤  ≤ 65.04º and with
Miller indices hmin= -11, hmax= 11, kmin= -1, kmax= 14, lmin= -16, lmax= 16. 2954 independent
reflections were merged with R = 0.0155 to 2822 unique reflections. The intensity data were corrected
for Lorentz and polarisation effect.
The structure was solved by direct methods using SHELX86 [11] and SIR92 [12] program and re-
fined by anisotropic full-matrix least squares on F2 (SHELXL93 [13]). The position of the H atoms
were generated from assumed geometry, checked on a difference Fourier map and refined isotropically
with common displacement parameter U1=0.056(2) Å2, U2=0.066(4) Å2 and U3=0.063(2) Å2,
U4=0.100(7) Å2 for all H atoms except H atoms attached to C(15)A(B), C(16)A(B) (peripheral atoms)
for molecules A and B, respectively  and methyl type atoms C(18)A(B) with isotropic displacement
parameters fixed to 1.5 Ueq of the parent atoms. Final R-factor was R = 0.0308 for 404 parameters and
2954 reflections. Scattering factors were taken from SHELXL93. Conformational calculations were
performed using the program RING [14]. Molecular graphics were drawn using ORTEP-III [15].
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Table 5. Crystal data and structure refinement.
Empirical formula C18 H22O4
Formula weight 302.36
Temperature 293(2) K
Wavelength 1.54178 A
Crystal system Monoclinic
Space group P21
Unit cell dimensions a = 9.745(5Å         . 
b = 12.071(5) Å      
c = 14.342(5) Å      
Volume 1629.2(12) Å3
Z 4
Density (calculated) 1.233 Mg/m3
Absorption coefficient 0.699 mm-1
F(000) 324
Crystal size 0.5 × 0.3 × 0.2 mm
Theta range for data collection 3.19 to 65.04 °
Index ranges -11 ≤ h ≤11, -1 ≤ k ≤14, -16 ≤ l ≤ 16
Reflections collected 5499
Independent reflections 2954 [R(int) = 0.0155]
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2954 / 1 / 404
Goodness-of-fit on F2 1.094
)LQDO5LQGLFHV>,!1,@ R1 = 0.0308, wR2 = 0.0886
R indices (all data) R1 = 0.0327, wR2 = 0.0900
Absolute structure parameter 0.1(2)
Extinction coefficient 0.0022(4)
Largest diff. peak and hole 0.147 and -0.122 e Å-3
Table 6. Selected bond lengths [Å] and angles [°].
O(3A)-C(3A) 1.217(4) O(3B)-C(3B 1.217(4)
O(4A)-C(5A) 1.441(3) O(4B)-C(4B) 1.438(4)
O(4A)-C(4A) 1.454(3) O(4B)-C(5B) 1.441(3)
O(10A)-C(10A) 1.433(3) O(10B)-C(10B) 1.424(3)
O(17A)-C(17A)) 1.210(3 O(17B)-C(17B) 1.212(4)
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Continuation of the Table 6.
C(1A)-C(2A) 1.329(4) C(1B)-C(2B) 1.328(4)
C(1A)-C(10A) 1.504(3) C(1B)-C(10B) 1.500(4)
C(2A)-C(3A) 1.455(4) C(2B)-C(3B) 1.450(5)
C(3A)-C(4A) 1.487(4) C(3B)-C(4B) 1.478(5)
C(4A)-C(5A) 1.475(4) C(4B)-C(5B) 1.460(4)
C(5A)-C(6A) 1.501(3) C(5B)-C(6B) 1.498(4)
C(5A)-C(10A) 1.519(3) C(5B)-C(10B) 1.516(3)
C(13A)-C(18A) 1.541(4) C(13B)-C(18B) 1.551(4)
C(14A)-C(15A) 1.533(3) C(14B)-C(15B) 1.528(4)
C(15A)-C(16A) 1.540(4) C(15B)-C(16B) 1.541(5)
C(16A)-C(17A) 1.510(4) C(16B)-C(17B) 1.513(6)
C(5A)-O(4A)-C(4A) 61.3(2) C(4B)-O(4B)-C(5B) 60.9(2)
C(2A)-C(1A)-C(10A) 124.8(2) C(2B)-C(1B)-C(10B) 125.8(3)
C(1A)-C(2A)-C(3A) 122.2(2) C(1B)-C(2B)-C(3B) 121.4(3)
O(3A)-C(3A)-C(2A) 123.7(3) O(3B)-C(3B)-C(2B) 123.1(3)
O(3A)-C(3A)-C(4A) 120.3(3) O(3B)-C(3B)-C(4B) 120.1(3)
C(2A)-C(3A)-C(4A) 116.0(2) C(2B)-C(3B)-C(4B) 116.7(2)
O(4A)-C(4A)-C(5A) 58.9(2) O(4B)-C(4B)-C(5B) 59.6(2)
O(4A)-C(4A)-C(3A) 113.0(2) O(4B)-C(4B)-C(3B) 112.7(3)
C(5A)-C(4A)-C(3A) 119.7(2) C(5B)-C(4B)-C(3B) 120.9(2)
O(4A)-C(5A)-C(4A) 59.8(2) O(4B)-C(5B)-C(4B) 59.4(2)
O(4A)-C(5A)-C(6A) 114.3(2) O(4B)-C(5B)-C(6B) 114.7(2)
C(4A)-C(5A)-C(6A) 119.1(2) C(4B)-C(5B)-C(6B) 119.3(2)
O(4A)-C(5A)-C(10A) 115.8(2) O(4B)-C(5B)-C(10B) 115.6(2)
C(4A)-C(5A)-C(10A) 119.5(2) C(4B)-C(5B)-C(10B) 119.3(2)
C(17A)-C(13A)-C(18A) 104.8(2) C(12B)-C(13B)-C(18B) 111.3(2)
C(12A)-C(13A)-C(18A) 111.6(2) C(17B)-C(13B)-C(18B) 104.2(2)
C(14A)-C(13A)-C(18A) 113.8(2) C(14B)-C(13B)-C(18B) 114.0(2)
O(17A)-C(17A)-C(16A) 125.1(2) O(17B)-C(17B)-C(16B) 126.6(3)
O(17A)-C(17A)-C(13A) 126.5(2) O(17B)-C(17B)-C(13B) 125.5(3)
O(3A)-C(3A)-C(4A)-O(4A) -129.1(3) O(3B)-C(3B)-C(4B)-O(4B) -121.1(3)
O(3A)-C(3A)-C(4A)-C(5A) 164.7(3) O(3B)-C(3B)-C(4B)-C(5B) 171.7(3)
O(4A)-C(5A)-C(10A)-O(10A) 75.7(2) O(4B)-C(5B)-C(10B)-O(10B) 74.4(3)
C(18A)-C(13A)-C(14A)-C(8A) 64.6(2) C(18B)-C(13B)-C(14B)-C(8B) 64.7(3)
C(18A)-C(13A)-C(17A)-O(17A) -91.7(3) C(18B)-C(13B)-C(17B)-O(17B) -91.4(4)
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Crystallographic data (excluding structure factors) for the structure reported in this paper have been
deposited with the Cambridge Crystallographic Data Centre as supplementary publication no.CCDC -
132357.  Copies of the data can be obtained free of charge on application to The Director, CCDC,12
Union Road, Cambridge CB2 1EZ, UK (fax: int.code +(1223) 336-033, E-mail:
teched@chemcrys.cam.ac.uk
Biochemistry
Materials and methods
Stock solution of investigated compounds were made in DMSO at a concentration of 10.58 mM,
and it was diluted by nutritient medium (RPMI 1640 medium supplemented with l-glutamine (3
mmol/L), streptomycin 100 µg/mL and penicillin 100 IU/mL, 10% heat inactivated fetal bovine serum,
FBS and 25 mM Hepes, adjusted to pH 7.2 by bicarbonate solution) to various final concentrations. 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT); RPMI 1640 cell culture medium
and fetal bovine serum (FBS), were purchased from Sigma Chemicals (St. Luis, MO, U.S.A.). MTT
was dissolved, 5 mg/mL in phosphate buffer saline pH 7.2, and filtered through Milipore filter, 0.22
µm, before use.
Cell culture
Human malignant melanoma Fem-x cells, and human cervix carcinoma HeLa cells were maintained
as a monolayer culture in the same nutritient medium The cells were grown at 37 °C in 5% CO2 and
humidified air atmosphere.
Treatment of Fem-x and HeLa cells
Target cells were seeded (2000 cells in 100 µL of nutrient medium  per well), into 96-well micro-
titer flat bottomed plates and twenty hours later, five different concentrations of the investigated com-
pound were added to the wells in triplicate, to various final concentrations, except to the control wells
where only a nutritient medium was added to the cells. Nutritient medium with corresponding concen-
trations of compound, but void of cells was used as blank, in triplicate too. The experiment was re-
peated three times.
Determination of HeLa and Fem-x cell survival
Cell survival was determined as reported earlier [16] by MTT test 48 h after the drug addition.
Briefly, MTT solution (5 mg / mL PBS) was added to each well. Samples were incubated for further
four hours at 37 °C in 5% CO2 and humidified air atmosphere. Then, 10% SDS in 0.01 M HCl was
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added to the wells. Optical density (OD) at 570 nm was red the next day. To get cell survival (%), op-
tical density at 570 nm of a sample with cells grown in the presence of various concentration of inves-
tigated agent (OD), was divided with control optical density ODc, (the OD of cells grown only in nu-
tritient medium) ×100. Concentration IC50 was defined as the concentration of a drug needed to inhibit
cell survival by 50%, compared with vehicle-treated control.
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